Stent-based release of a selective PDGF-receptor blocker from the bis-indolylmethanon class inhibits restenosis in the rabbit animal model

Vascular Pharmacology

Volumn 52, Issue 1-2, 2010, Pages 55-62

  Jandt, Enrico ^a   Mutschke, Oliver ^a   Mahboobi, Siavosh ^b   Uecker, Andrea ^a   Platz, Ronny ^a   Berndt, Alexander ^a   Böhmer, Frank D ^a   Figulla, Hans R ^a   Werner, Gerald S ^a,c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c KLINIKUM DARMSTADT   (Germany)

Author keywords

Bis(1H 2 indolyl)methanone; PDGF; Rabbit; Restenosis; Stent

Indexed keywords

CYCLINE; CYTOKINE RECEPTOR ANTAGONIST; D 65495; DIMETHYL SULFOXIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; TETRAHYDROFURAN; UNCLASSIFIED DRUG; INDOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTICLE; BALLOON DILATATION; BARE METAL STENT; BLOOD VESSEL WALL; CONTROLLED STUDY; CORONARY STENT; CYTOSTASIS; DEVICE REMOVAL; DRUG ELUTING STENT; FEMALE; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS; SCORING SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; CORONARY RESTENOSIS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; FEMALE; ILIAC ARTERY; INDOLES; RABBITS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 76049097740     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.11.001     Document Type: Article

References (44)

1. Asahara, Bauters, Pastore, Kearney, Rossow, Bunting, Ferrara, Symes, and Isner. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91 (1995) 2793-2801
2. Banai, Wolf, Golomb, Pearle, Waltenberger, Fishbein, Schneider, Gazit, Perez, Huber, Lazarovichi, Rabinovich, Levitzki, and Gertz. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 97 (1998) 1960-1969
3. Banai, Gertz, Gavish, Chorny, Perez, Lazarovichi, Ianculuvich, Hoffmann, Orlowski, Golomb, and Levitzki. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc. Res. 64 (2004) 165-171
4. Banai, Chorny, Gertz, Fishbein, Gao, Lazarovichi, Gazit, Levitzki, and Golomb. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 26 (2005) 451-461
5. Bauters, and Isner. The biology of restenosis. Prog. Cardiovasc. Dis. 40 (1997) 107-116
6. Bilder, Wentz, Leadley, Amin, Byan, O'Conner, Needle, Galczenski, Bostwick, Kasiewski, Myers, Spada, Merkel, Ly, Persons, Page, Perrone, and Dunwiddie. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation 99 (1999) 3292-3299
7. Bilder, Amin, Morgan, McVey, Needle, Galczenski, Leadley, He, Myers, Spada, Luo, Natajaran, and Perrone. Stent-induced restenosis in the swine coronary artery is inhibited by a platelet-derived growth factor receptor tyrosine kinase inhibitor, TKI963. J. Cardiovasc. Pharmacol. 41 (2003) 817-829
8. Biondi-Zoccai, Lotrionte, Moretti, Agostoni, Sillano, Laudito, and Sheiban. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher). Minerva Cardioangiol. 56 (2008) 55-65
9. Carter, Laird, Farb, Kufs, Wortham, and Virmani. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J. Am. Coll. Cardiol. 24 (1994) 1398-1405
10. Chen, Han, Lin, Zhen, Song, Teng, Chen, Chen, Zhang, and Hui. PDGF-D contributes to neointimal hyperplasia in rat model of vessel injury. Biochem. Biophys. Res. Commun. 329 (2005) 976-983
11. Dorffler-Melly, Koopman, Prins, and Buller. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst. Rev. (2005) CD002071
12. Erbel, Haude, Hopp, Franzen, Rupprecht, Heublein, Fischer, de Jaegere, Serruys, Rutsch, and Probst. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N. Engl. J. Med. 339 (1998) 1672-1678
13. Ferns, Raines, Sprugel, Motani, Reidy, and Ross. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253 (1991) 1129-1132
14. Fishbein, Chorny, Banai, Levitzki, Danenberg, Gao, Chen, Moerman, Gati, Goldwasser, and Golomb. Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb. Vasc. Biol. 21 (2001) 1434-1439
15. Grassman, Leya, Fareed, Lewis, Bacher, Loeb, and Moran. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. J. Invasive Cardiol. 13 (2001) 723-728
16. Hacker, Griffin, Guttormsen, Stoker, and Wolff. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. J. Invasive Cardiol. 19 (2007) 269-274
17. Jackson, Raines, Ross, and Reidy. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 13 (1993) 1218-1226
18. Joner, Finn, Farb, Mont, Kolodgie, Ladich, Kutys, Skorija, Gold, and Virmani. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48 (2006) 193-202
19. Kim, Park, Kim, Piao, Kwon, Hwang, Youn, Park, Yun, Sachinidis, Kim, Cho, and Ahn. Local delivery of green tea catechins inhibits neointimal formation in the rat carotid artery injury model. Heart Vessels 19 (2004) 242-247
20. Kim, Han, Hong, Hwang, Hwang, Yoo, Jin, Lee, Yu, Lee, Kang, and Yun. Cudratricusxanthone A isolated from the root bark of Cudrania tricuspidata inhibits the proliferation of vascular smooth muscle cells through the suppression of PDGF-receptor beta tyrosine kinase. Biol. Pharm. Bull. 30 (2007) 805-809
21. Korovesis, Karvouni, Giazitzoglou, and Katritsis. Drug-eluting stents: immediate and long-term results. Hellenic J. Cardiol. 46 (2005) 330-335
22. Leppanen, Janjic, Carlsson, Levin, Janjic, Vargeese, Green, Bergqvist, Ostman, and Heldin. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb. Vasc. Biol. 20 (2000) E89-E95
23. Leppanen, Rutanen, Hiltunen, Rissanen, Turunen, Sjoblom, Bruggen, Backstrom, Carlsson, Buchdunger, Bergqvist, Alitalo, Heldin, Ostman, and Yla-Herttuala. Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 109 (2004) 1140-1146
24. Levitzki. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc. Res. 65 (2005) 581-586
25. Li, Fukuda, Kunimoto, Yokoyama, Hagikura, Kawano, Takayama, Honye, Kobayashi, Mugishima, Saito, and Serie. Stent-based delivery of antisense oligodeoxynucleotides targeted to the PDGF A-chain decreases in-stent restenosis of the coronary artery. J. Cardiovasc. Pharmacol. 48 (2006) 184-190
26. Losordo, Isner, and Diaz-Sandoval. Endothelial recovery: the next target in restenosis prevention. Circulation 107 (2003) 2635-2637
27. Mahboobi, Teller, Pongratz, Hufsky, Sellmer, Botzki, Uecker, Beckers, Baasner, Schachtele, Uberall, Kassack, Dove, and Bohmer. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J. Med. Chem. 45 (2002) 1002-1018
28. Mehilli, Kastrati, Wessely, Dibra, Hausleiter, Jaschke, Dirschinger, Schomig, 2006. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation Jan 17;113(2):273-9.
29. Panek, Dahring, Olszewski, and Keiser. PDGF receptor protein tyrosine kinase expression in the balloon-injured rat carotid artery. Arterioscler Thromb. Vasc. Biol. 17 (1997) 1283-1288
30. Pendyala, Jabara, Shinke, Chronos, Robinson, Li, and Hou. Drug-eluting stents: present and future. Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 105-115
31. Pompili, Gordon, San, Yang, Muller, Nabel, and Nabel. Expression and function of a recombinant PDGF B gene in porcine arteries. Arterioscler Thromb. Vasc. Biol. 15 (1995) 2254-2264
32. Schwartz. Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest. 100 (1997) S87-S89
33. Schwartz, Edelman, Carter, Chronos, Rogers, Robinson, Waksman, Weinberger, Wilensky, Jensen, Zuckerman, and Virmani. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 106 (2002) 1867-1873
34. Serruys, Heyndrickx, Patel, Cummins, Kleijne, and Clowes. Effect of an anti-PDGF-beta-receptor-blocking antibody on restenosis in patients undergoing elective stent placement. Int. J. Cardiovasc. Interv. 5 (2003) 214-222
35. Sindermann, Verin, Hopewell, Rodemann, and Hendry. Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc. Res. 63 (2004) 22-30
36. Slavin, Chhabra, and Tobis. Drug-eluting stents: preventing restenosis. Cardiol. Rev. 15 (2007) 1-12
37. Steffel, Eberli, Luscher, and Tanner. Drug-eluting stents - what should be improved?. Ann. Med. 40 (2008) 242-252
38. Steinberg, and Satler. Drug-eluting stent thrombosis. Minerva Cardioangiol. 56 (2008) 127-137
39. Stone, Moses, Ellis, Schofer, Dawkins, Morice, Colombo, Schampaert, Grube, Kirtane, Cutlip, Fahy, Pocock, Mehran, and Leon. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356 (2007) 998-1008
40. ten Berg, Kelder, Suttorp, Verheugt, and Plokker. A randomized trial assessing the effect of coumarins started before coronary angioplasty on restenosis: results of the 6-month angiographic substudy of the Balloon Angioplasty and Anticoagulation Study (BAAS). Am. Heart J. 145 (2003) 58-65
41. Ueda, Becker, Kasayuki, Kojima, Morita, and Tanaka. In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Am. J. Pathol. 149 (1996) 831-843
42. Werner, Schwarz, Prochnau, Fritzenwanger, Krack, Betge, and Figulla. Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: a strategy of extensive lesion coverage with drug-eluting stents. Catheter Cardiovasc. Interv. 67 (2006) 1-9
43. Yamasaki, Miyoshi, Oda, Watanabe, Miyake, Chan, Wang, Sun, Tang, McMahon, and Lipson. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis. Circ. Res. 88 (2001) 630-636
44. Zohlnhofer, Hausleiter, Kastrati, Mehilli, Goos, Schuhlen, Pache, Pogatsa-Murray, Heemann, Dirschinger, and Schomig. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J. Am. Coll. Cardiol. 46 (2005) 1999-2003